Andrology最新文献

{"title":"A North American preconception cohort study of cannabis use and semen quality.","authors":"Marlon D Joseph, Dmitrii Krivorotko, Martha R Koenig, Amelia K Wesselink, Michael L Eisenberg, Greg J Sommer, Kenneth J Rothman, Sherri O Stuver, Elizabeth E Hatch, Lauren A Wise","doi":"10.1111/andr.70056","DOIUrl":"https://doi.org/10.1111/andr.70056","url":null,"abstract":"<p><strong>Background: </strong>Recreational and medicinal use of cannabis is increasing among North American reproductive-aged couples. Studies of cannabis use and semen quality are limited and have produced inconsistent findings.</p><p><strong>Objectives: </strong>We examined the association between male cannabis use and semen parameters.</p><p><strong>Materials and methods: </strong>We analyzed data from 1654 semen samples contributed by 921 male participants in Pregnancy Study Online (PRESTO), a North American preconception cohort study. Participants aged ≥21 years completed a baseline questionnaire on which they reported their cannabis use within the past 2 months. After enrollment, we invited participants to perform at-home semen testing. We used linear regression to estimate percent differences in mean semen parameter values (%D) and 95% confidence intervals (CI) for associations between cannabis use and semen volume (mL), total sperm count (TSC, million), sperm concentration (million/mL), motility (%), and total motile sperm count (TMSC, million), controlling for potential confounders. We used log-binomial regression to estimate risk ratios (RRs) for low semen quality based on 2021 World Health Organization cut-points.</p><p><strong>Results: </strong>Overall, 22.6% of participants reported current cannabis use and 3.3% reported daily use. Nearly 6% of participants had low semen volume (≤1.5 mL), 13% low sperm concentration (≤15 million/L), 8% low TSC (≤39 million), 25% low sperm motility (≤40%), and 11% low TMSC (≤16 million). Adjusted %Ds (95% CIs) comparing current cannabis use versus non-use were -3.2 (-9.1, 2.7) for semen volume, 3.5 (-10.3, 19.5) for sperm concentration, -0.6 (-14.3, 15.3) for TSC, 2.5 (-2.9, 8.0) for motility, and 3.0 (-13.4, 22.4) for TMSC. Cannabis use ≥1 times/week (vs. non-use) was associated with low semen volume (RR = 2.16, 95% CI = 0.93-5.04). Associations were imprecise and showed no monotonic association between frequency of cannabis use and the semen parameters evaluated.</p><p><strong>Conclusion: </strong>In this North American preconception cohort study, current cannabis use was not appreciably associated with semen quality.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacogenetics of follicle-stimulating hormone action in the male.","authors":"Andrea Graziani, Giuseppe Grande, Raffele Scafa, Riccardo Selice, Andrea Garolla, Maria Santa Rocca, Cinzia Vinanzi, Alberto Ferlin","doi":"10.1111/andr.70053","DOIUrl":"https://doi.org/10.1111/andr.70053","url":null,"abstract":"<p><p>Male factor infertility (MFI) is involved in half of the cases of couple infertility. The follicle-stimulating hormone (FSH) therapy is considered efficient to improve semen parameters and pregnancy rate in patients with idiopathic MFI, following the lesson learned from hypogonadotropic hypogonadism. However, while in patients with hypogonadotropic hypogonadism FSH therapy, in combination with human chorionic gonadotropin (hCG), is a well-established treatment, in patients with MFI the effects of the FSH therapy are variable and unpredictable. The FSH therapy in MFI should be a personalized treatment, tailored on the characteristics of the male patient and the couple. The pivotal aspect is the accurate identification of patients who might benefit from such treatment (responders) from those who might not (nonresponders). To date, selection of patients to be treated is based on history, physical examination, semen analysis, and hormonal assessment. However, these parameters cannot adequately identify a priori responder patients. Furthermore, tailored management should include pharmacological adaptation (dosage and duration of the therapy), as happens during ovarian hyperstimulation in assisted reproductive technologies. In a fully personalized therapy, pharmacogenetic factors must be considered. In this paper, we describe the evidence dealing with the pharmacogenetics of the FSH therapy in MFI, presenting the physiological and physiopathological basis and the pharmacogenetics studies dealing with effects of polymorphisms in the beta-subunit of FSH (FSHB) and the FSH receptor (FSHR) gene. According to the evidence so far available, genetic evaluation of FSHB and FSHR is recommended only for research purposes, since the data are not conclusive and even contrasting. Furthermore, the evidence so far is derived from quite small studies with different endpoints considered and relatively few cases. Better studies that consider the combined effect of several FSHB and FSHR gene polymorphisms, together with clinical, biochemical, seminal and testicular cytology, are necessary to develop an algorithm that might predict the response to the FSH treatment.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gonadal function in males with WFS1 spectrum disorder (Wolfram syndrome)-A European cohort perspective.","authors":"Julia Rohayem, Olivia Cunningham, Denise Williams, Joachim Wistuba, Liam McCarthy, Timothy G Barrett, Renuka P Dias","doi":"10.1111/andr.70049","DOIUrl":"https://doi.org/10.1111/andr.70049","url":null,"abstract":"<p><strong>Background: </strong>WFS1 spectrum disorder, also known as Wolfram syndrome (WS) is an ultra-rare (<1:500,000; ORPHA: 3463) monogenic (OMIM #222300) progressive neuroendocrine and neurodegenerative disorder, characterised by early-onset insulin-dependent diabetes, optic atrophy, central diabetes insipidus and sensi-neuronal deafness. It is caused predominantly by bi-allelic mutations in the WFS1 gene and exceptionally in the WFS2-gene. There is very limited published data on gonadal function in young people with WS. Expansion of the phenotype has previously included suggestions of abnormalities in puberty in adolescents with (WS) but with little detail.^1-3 AIM: To assess testicular function and pubertal progression in a cohort of adolescent and young adult patients with classical WFS1 spectrum disorder (WS).</p><p><strong>Methods: </strong>Retrospective case notes review of national patient cohorts comprising 21 males with WS aged 16-30 years. All patients were treated in two tertiary European health care centres: in Birmingham, UK and Münster, Germany. Hormonal parameters reflecting hypothalamic-pituitary-gonadal axis function and treatment with sex hormones were assessed. In addition, the presence or absence of erectile dysfunction was explored. In a subset of men, semen data were analysed. In one young man, testicular biopsies were examined histologically using light and electron microscopy.</p><p><strong>Results: </strong>Severely delayed or arrested puberty was observed in 57% of male adolescents with WS, necessitating testosterone replacement for completion of pubertal development. Subclinical (compensated) hypergonadotropic hypogonadism with still adequate testosterone serum concentration for age, but elevated LH/FSH was observed in 28.6% (n = 6). In two males, aged 19 and 16 years (9.5%), inadequately low LH/FSH and testosterone levels indicated hypogonadotropic hypogonadism. In the subset of males with normal puberty and normal endocrine testicular function (43% of male patients), the oldest, aged 30 years had normal sperm count in semen. Another young man had oligozoospermia at age 20, but azoospermia at age 25 years. Histology of his testicular tissues evidenced structural alterations of Leydig and Sertoli cells and tubular atrophy with various stages of tubular degeneration and meiotic arrest of spermatogenesis.</p><p><strong>Conclusion: </strong>Endocrine testicular function and reproductive capacity are impaired in males with WS potentially due to premature degeneration of the testes, with 57% of adolescents developing hypogonadism with pubertal arrest.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Season of birth and variations in male reproductive health: A population-based cohort study.","authors":"Anne Gaml-Sørensen, Nis Brix, Sandra Søgaard Tøttenborg, Karin Sørig Hougaard, Siri Eldevik Håberg, Mikko Myrskylä, Gunnar Toft, Jens Peter Ellekilde Bonde, Cecilia Høst Ramlau-Hansen","doi":"10.1111/andr.70052","DOIUrl":"https://doi.org/10.1111/andr.70052","url":null,"abstract":"<p><strong>Background: </strong>Season of birth has been associated with various later reproductive health outcomes in women, but little is known on the potential associations in men.</p><p><strong>Objectives: </strong>To investigate the association between season of birth and semen characteristics, testes volume and reproductive hormone levels in young men.</p><p><strong>Materials and methods: </strong>We conducted a follow-up study of 1058 young men, born 1998 to 2000, from the Fetal Programming of Semen Quality (FEPOS) cohort, Denmark, 2017-2019. Information on season of birth was obtained from the Danish Civil Registration System, and information on male reproductive health outcomes was obtained at a clinical examination, where the men provided a semen and a blood sample and measured testes volume. Percentage differences in semen characteristics, testes volume and reproductive hormone levels were calculated according to season of birth (binary (main analysis): summer; winter and categorised by four calendar seasons and by calendar month (subanalyses)) using adjusted regression models and visualisalised according to month of birth.</p><p><strong>Results: </strong>Testosterone levels were lower (-3% (95% CI: -7%; 0%)) and oestradiol levels were higher (10% (95% CI: 2%; 20%)) in men born during the winter half-year than the summer half-year. The finding of higher oestradiol in men born during the winter was corroborated in analyses of calendar season and month of birth. Other reproductive health outcomes displayed some variation; however, estimates were generally close to null.</p><p><strong>Discussion: </strong>Although oestradiol levels seemed higher in men born during the winter half-year, this could be a chance finding. Since pregnancies usually span three seasons, this finding could therefore also reflect an association between early pregnancy during the summer and oestradiol levels.</p><p><strong>Conclusion: </strong>We observed higher oestradiol levels in men born during the winter than during the summer half-year. For the remaining reproductive health outcomes, the observed fluctuations may reflect random variation.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of MEF2A, MEF2C, and MEF2D interactomes in basal and Fsk-stimulated mouse MA-10 Leydig cells.","authors":"Karine de Mattos, Marie-Pier Scott-Boyer, Arnaud Droit, Robert S Viger, Jacques J Tremblay","doi":"10.1111/andr.70051","DOIUrl":"https://doi.org/10.1111/andr.70051","url":null,"abstract":"<p><strong>Background: </strong>Myocyte enhancer factor 2 transcription factors regulate essential transcriptional programs in various cell types. The activity of myocyte enhancer factor 2 factors is modulated through interactions with cofactors, chromatin remodelers, and other regulatory proteins, which are dependent on cell context and physiological state. In steroidogenic Leydig cells, MEF2A, MEF2C, and MEF2D are key regulators of genes involved in steroid hormone synthesis, reproductive function, and oxidative stress defense. However, the specific network of myocyte enhancer factor 2-interacting proteins in Leydig cells remains unknown.</p><p><strong>Objective: </strong>To identify the interactome of each MEF2 factor present in Leydig cells.</p><p><strong>Materials and methods: </strong>TurboID proximity-mediated biotinylation combined with mass spectrometry and bioinformatic analyses were used to identify the protein‒protein interaction networks of MEF2A, MEF2C, and MEF2D in MA-10 Leydig cells under basal and stimulated conditions.</p><p><strong>Results: </strong>We identified 109 potential myocyte enhancer factor 2-interacting proteins, including some previously known myocyte enhancer factor 2 partners. The interactome for each myocyte enhancer factor 2 factor is dynamic and exhibits unique and shared interaction networks between basal and stimulated conditions. Further analysis through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment categorized these interactions, revealing involvement in pathways related to cellular metabolism, transcriptional regulation, and steroidogenesis.</p><p><strong>Discussion and conclusion: </strong>These findings suggest that myocyte enhancer factor 2 factors can participate in diverse transcriptional activities, capable of gene activation or repression, depending on different protein‒protein interactions. In addition, the differential interactome for each myocyte enhancer factor 2 factor suggests unique regulatory roles for each factor in modulating Leydig cell function. Overall, this study provides new mechanistic insights into myocyte enhancer factor 2 action in Leydig cells by identifying interacting partners that likely influence their functions.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of artificial oocyte activation with calcium ionophore on ICSI outcomes using surgically retrieved spermatozoa: A comprehensive analysis.","authors":"Adva Aizer, Meirav Noach-Hirsh, Chen Shimon, Olga Dratviman-Storobinsky, Lilach Haham Marom, Ettie Maman, Raoul Orvieto","doi":"10.1111/andr.70047","DOIUrl":"https://doi.org/10.1111/andr.70047","url":null,"abstract":"<p><strong>Background: </strong>Intracytoplasmic sperm injection (ICSI) is an effective technique for addressing male infertility. However, fertilization challenges persist, particularly with spermatozoa obtained through testicular sperm procedures.</p><p><strong>Objectives: </strong>This study evaluates the impact of artificial oocyte activation (AOA) on ICSI outcomes using surgically retrieved spermatozoa (motile, immotile, fresh, and frozen), including results from vitrified-warmed embryo transfers and investigating potential improvements in clinical outcomes.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on 73 testicular sperm extraction (TESE)-ICSI cycles involving 57 patients. Outcomes were compared between AOA and non-AOA groups using a sibling oocyte model.</p><p><strong>Results: </strong>Fertilization rates were similar between AOA and non-AOA groups (53.2% vs. 52.3%). However, AOA showed a non-significant increase in TQE rates (64.4% vs. 54.7%, p = 0.067). Cumulative live-birth rates were comparable between AOA (19.3%) and non-AOA (21.6%) groups (p = 0.77). Notably, AOA significantly enhanced TQE rates when used with fresh spermatozoa (65.9% vs. 49.4%, p = 0.026) and non-progressive/immotile spermatozoa (72.7% vs. 51.1%, p = 0.031), yet had minimal effect with motile spermatozoa. There were no significant differences in embryo development timings between the groups. Obstetric and neonatal outcomes were comparable in-between groups, supporting the safety of AOA in this setting.</p><p><strong>Discussion: </strong>AOA appears to positively influence ICSI outcomes when using fresh and non-progressive/immotile spermatozoa. While the overall morphokinetics of embryo development were not affected, the improvement in TQE rates highlights AOA's potential in enhancing embryo quality. The consistent trends toward higher clinical pregnancy and live-birth rates further support its clinical utility.</p><p><strong>Conclusion: </strong>The study demonstrates that AOA significantly improves TQE rates, without negatively impacting overall morphokinetics or obstetric and neonatal outcomes. While the results suggest AOA's potential for specific subsets of male factor infertility cases, further research is needed to confirm its long-term safety and efficacy before broader clinical applications.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The absence of both RIBC1 and RIBC2 induces decreased sperm motility and litter size in male mice.","authors":"Kento Katsuma, Keisuke Shimada, Shingo Tonai, Daisuke Mashiko, Rie Iida-Norita, Yuki Kaneda, Haruhiko Miyata, Masahito Ikawa","doi":"10.1111/andr.70045","DOIUrl":"https://doi.org/10.1111/andr.70045","url":null,"abstract":"<p><strong>Background: </strong>RIBC1 (RIB43A domain with coiled-coils 1) and RIBC2 (RIB43A domain with coiled-coils 2) are homolog proteins of RIB43a which is localized to microtubules in the cilia and flagella of unicellular organisms. Cryo-electron microscopy and artificial intelligence studies showed that RIBC1 and RIBC2 are microtubule inner proteins (MIPs) localized in the inner lumen of the doublet microtubules (DMTs) in mouse sperm flagella. However, the function of RIBC1 and RIBC2 in mammalian reproduction and sperm flagella is still unknown.</p><p><strong>Objective: </strong>To clarify the function of RIBC1 and RIBC2 in mouse spermatozoa.</p><p><strong>Materials and methods: </strong>We generated Ribc1 knockout (KO), Ribc2 KO, and Ribc1 and Ribc2 double-knockout (Ribc1/2 DKO) mice using the CRISPR/Cas9 system and analyzed their phenotypes.</p><p><strong>Results: </strong>We revealed that the loss of either RIBC1 or RIBC2 alone did not affect male fertility, but the absence of both caused a decrease in pup numbers. Sperm motility analysis showed that Ribc1 KO spermatozoa had reduced velocity, but Ribc2 KO sperm velocities were comparable with WT mice. However, Ribc1/2 DKO sperm velocities were significantly lower than those from Ribc1 KO mice. No structural abnormalities in the axonemal structure at the transmission electron microscope (TEM) level and no abnormalities in the flagellar waveform pattern were observed in Ribc1/2 DKO spermatozoa.</p><p><strong>Discussion and conclusion: </strong>Both RIBC1 and RIBC2 are not significant for maintaining the axonemal structure in mouse spermatozoa, but both proteins function cooperatively in sperm motility. This result may indicate that minor structural changes due to RIBC protein absence are not detected at the TEM level, and RIBC2 function depends on RIBC1 in sperm motility. We think that reduced litter size in Ribc1/2 DKO mice is caused by reduced sperm motility due to minor structural abnormalities caused by the loss of two RIBC proteins.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Penile vascular status in young men living with HIV experiencing erectile dysfunction: A comparative cross-sectional pilot study.","authors":"Giorgio Tiecco, Andrea Delbarba, Cosimo Colangelo, Marco Di Gregorio, Paolo Facondo, Matteo Riva, Carlo Cappelli, Emanuele Focà, Francesco Castelli, Eugenia Quiros-Roldan","doi":"10.1111/andr.70050","DOIUrl":"https://doi.org/10.1111/andr.70050","url":null,"abstract":"<p><strong>Background: </strong>Erectile dysfunction in people living with HIV is a multifactorial disease, but the role of penile vascular status assessed by dynamic penile color Doppler echography is underexplored.</p><p><strong>Objectives: </strong>This study assessed penile vascular status in young males living with HIV experiencing erectile dysfunction, comparing them to HIV-negative controls stratified into young (<50 years) and middle-aged (51-60 years).</p><p><strong>Materials and methods: </strong>This monocentric, comparative cross-sectional study included young males living with HIV (18-50 years) on antiretroviral therapy for >12 months and HIV-negative individuals presenting with erectile dysfunction. We used dynamic penile color Doppler echography to evaluate penile vascular parameters such as peak systolic velocity, intima-media thickness, and end-diastolic velocity. Statistical analyses, including k-means clustering and stepwise multivariate logistic regression, assessed associations between clinical variables and vascular parameters.</p><p><strong>Results: </strong>Of 310 young males living with HIV screened, 50 (16.1%) reported erectile dysfunction and were enrolled, with 97 HIV-negative individuals included as controls. Pathological intima-media thickness was significantly higher (p = 0.004) in young males living with HIV (76%) than in young controls (49%) but comparable to middle-aged controls (76.1%). Stepwise multivariate logistic regression identified belonging to the young control group, compared to young males living with HIV, as a protective factor against pathological intima-media thickness (OR 0.353, 95% CI 0.138-0.902, p = 0.0295), while increasing age was a significant risk factor (OR 1.09, 95% CI 1.01-1.18, p = 0.0247). Relative inhomogeneity of clusters was tested demonstrating that membership in either the people living with HIV or HIV-negative group was a significant predictor of cluster assignment based on dynamic penile color Doppler echography parameters, independent of age (p = 0.0025).</p><p><strong>Discussion and conclusions: </strong>This study is the first to utilize dynamic penile color Doppler echography to evaluate erectile dysfunction in young males living with HIV, highlighting the association between HIV and early vascular alterations. Clinicians should incorporate routine sexual health evaluations into routinary out-patients visits, using erectile dysfunction as a potential indicator for further vascular screening and early intervention.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semen quality in patients with testicular cancer is associated with age and with greatly elevated levels of beta human chorionic gonadotropin.","authors":"Klaus-Peter Dieckmann, Johanna Hochmuth-Tisch, Andrea Salzbrunn, Cord Matthies, Kathrein von Kopylow, Marta Godlewska, Christian Wülfing, Uwe Pichlmeier, Armin Soave, Christian Guido Ruf","doi":"10.1111/andr.70046","DOIUrl":"https://doi.org/10.1111/andr.70046","url":null,"abstract":"<p><strong>Background: </strong>Poor semen quality is a well-known feature in patients with testicular germ cell tumours (GCTs) at the time of diagnosis but the underlying biological reasons are incompletely understood.</p><p><strong>Objectives: </strong>This study aimed to identify GCT-specific clinical factors that are involved with poor semen quality in GCT patients.</p><p><strong>Materials and methods: </strong>Pre-orchiectomy ejaculate volume (EV), total sperm count (TSC), and proportion of progressive motility (PPM) were retrospectively analysed in 163 consecutive GCT patients. Their possible associations with the following clinical factors were evaluated: patients age, GCT histology, clinical stages, tumour size, serum levels of tumour markers and of follicle stimulating hormone (FSH) and luteinizing hormone (LH). Statistical methods involved comparisons of various stratified subgroups of clinical characteristics by employing multivariable statistical analyses.</p><p><strong>Results: </strong>Patients > 40 years had significantly inferior results than patients < 30 years with respect to median EV (2 mL vs. 3.1 mL) and median PPM (25% vs. 40%). The median TSC was 75-80 million in mildly elevated levels of beta human chorionic gonadotropin (bHCG) opposed to only 22 million in greatly elevated levels. Elevated FSH indicated low sperm counts. GCT histology, tumour-size, and elevations of alpha fetoprotein levels were not associated with semen quality. The effect of clinical staging remained equivocal due to small numbers.</p><p><strong>Discussion and conclusion: </strong>Greatly elevated bHCG levels and age > 40 years are significantly associated with poor semen quality in GCT patients. The inverse association of age with semen quality is a novel finding in GCT patients that mirrors the physiological decline of male reproductive function with age but that still needs confirmation. As these two features are present in only a small proportion of patients, other factors such as the postulated testicular dysgenesis syndrome may be involved in the pathogenesis of poor semen quality in the majority of GCT patients.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role and implication of platelet-rich plasma in male factor infertility: A systematic review of human studies.","authors":"Karl H Pang","doi":"10.1111/andr.70048","DOIUrl":"https://doi.org/10.1111/andr.70048","url":null,"abstract":"<p><strong>Background: </strong>Cryopreservation causes sperm injury and the success of surgical sperm retrieval (SSR) for azoospermic men is just over half depending on the cause of azoospermia. The role of autologous platelet-rich plasma (PRP) in male factor infertility (MFI) is unclear.</p><p><strong>Objective: </strong>To conduct a systematic review of the role of PRP in MFI focusing on human studies.</p><p><strong>Methods: </strong>A systematic review was conducted using PubMed with reference to the PRISMA 2020 statement. The risk of bias assessment of the included studies was performed using the JBI assessment checklists. Outcome measures included the effects of PRP on cryopreservation, semen parameters, and SSR.</p><p><strong>Results: </strong>The search retrieved 119 articles and 10 met the pre-defined PICO criteria. These included 7 prospective studies, 1 randomised-controlled study, 1 retrospective study, and 1 case report. PRP appeared to improve semen parameters, decrease DNA fragmentation, improve recovery of cryopreserved sperm, and improve SSR rate. A case report demonstrated successful intracytoplasmic sperm injection and pregnancy following incubation of semen with PRP in a patient with previous failed IVF attempts.</p><p><strong>Discussion and conclusion: </strong>This is the first systematic review summarising data from human studies on the role of PRP in MFI. The inclusion criteria and outcomes of across studies varied, limiting the ability to conduct a quantitative analysis. Data from early studies on PRP in MFI are promising. However, there is a lack of well-designed clinical studies on this topic, and further research is needed to replicate current findings and evaluate the potential benefits of PRP in MFI.</p>","PeriodicalId":7898,"journal":{"name":"Andrology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}